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Abstract
Nasal NK/T cell lymphomas (NKTCL) are a subset of aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin’s
lymphomas. The role of EBV in pathogenesis of NKTCL is not clear. Intriguingly, EBV encodes more than 40 microRNAs
(miRNA) that are differentially expressed and largely conserved in lymphocryptoviruses. While miRNAs play a critical role in
the pathogenesis of cancer, especially lymphomas, the expression and function of EBV transcribed miRNAs in NKTCL are not
known. To examine the role of EBV miRNAs in NKTCL, we used microarray profiling and qRT-PCR to identify and validate
expression of viral miRNAs in SNK6 and SNT16 cells, which are two independently derived NKTCL cell lines that maintain the
type II EBV latency program. All EBV BART miRNAs except BHRF-derived miRNAs were expressed and some of these miRNAs
are expressed at higher levels than in nasopharyngeal carcinomas. Modulating the expression of BART9 with antisense RNAs
consistently reduced SNK6 and SNT16 proliferation, while antisense RNAs to BARTs-7 and -17-5p affected proliferation only
in SNK6 cells. Furthermore, the EBV LMP-1 oncoprotein and transcript levels were repressed when an inhibitor of BART9
miRNA was transfected into SNK6 cells, and overexpression of BART9 miRNA increased LMP-1 protein and mRNA expression.
Our data indicate that BART9 is involved in NKTCL proliferation, and one of its mechanisms of action appears to be
regulating LMP-1 levels. Our findings may have direct application for improving NKTCL diagnosis and for developing
possible novel treatment approaches for this tumor, for which current chemotherapeutic drugs have limited effectiveness.
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Introduction
EBV is a member of the herpes virus family and is a pre-
eminent human oncogenic virus with a causal relationship to
several malignancies, including endemic Burkitt’s lymphoma
(eBL), nasopharyngeal carcinoma (NPC), a proportion of gastric
carcinomas (GC), NKT-cell lymphomas (NKTCL), Hodgkin
disease (HD), post-transplant lymphoma-like disease (PTLD),
and leiomyosarcomas [1,2]. Within the context of AIDS, EBV is
associated with a proportion of non-Hodgkin lymphomas, almost
all HD, and leiomyosarcomas. The EBV genome contains over
170,000 bp encoding more than 80 genes. EBV gene expression
during latency and tumorgenesis consists of distinct combinations
of six nuclear proteins (EBNAs), three membrane proteins (LMPs)
and multiple noncoding RNAs, including over 40 miRNAs
[3,4,5,6,7]. While the EBV latent proteins have been investigated
intensively for some time, the contribution of EBV-encoded
miRNAs or altered cellular miRNA expression in EBV-induced
cancers has not been fully explored.
The EBV miRNAs were the first viral encoded miRNAs
discovered [6]. MiRNAs are ,22 nt transcripts that form
imperfect duplexes with target mRNAs and thereby inhibit their
expression. MiRNAs typically target the 39 UTR of mRNAs and
the average magnitude of repression of the encoded protein is
,30% [8]. EBV miRNAs are primarily derived from a group of
alternatively spiced RNAs transcribed from the BamH1A region
of the genome (BamA rightward transcripts or BARTs) [3,4,5,6].
The BARTs encode a large number of miRNAs and with the
exception of mir-BART2; the majority are derived from two
clusters. A cluster of 3 miRNAs has also been identified which are
derived from the BHRF1 gene. The sum total of at least 40 EBV-
encoded miRNAs dramatically increases the complexity of
potentially biologically active molecules encoded by EBV during
latent infection [9]. Like many of the miRNAs discovered to date,
the functions of the EBV-encoded miRNAs remain poorly
understood. It has been hypothesized that herpesvirus miRNAs,
including those encoded by EBV, Cytomegalovirus (CMV), and
Kaposi’s sarcoma- associated Herpesvirus (KHSV), may facilitate
the viral life cycle by blocking innate or adaptive immune
responses or by interfering with the appropriate regulation of
apoptosis, cell growth, or DNA replication in infected cells [9].
Herpesvirus miRNAs might also target mRNAs for viral genes
that regulate the productive lytic cycle, thus having a role in
maintaining latency or modulating productive lytic infection.
EBV-encoded miRNAs can target both viral and cellular genes.
EBV mir-BART2 targets the EBV DNA polymerase mRNA for
degradation [10], which inhibits lytic replication and miRNAs
from BART cluster 1 may target the viral LMP-1 protein [11]. In
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mir-BHRF1-3 targets the chemokine/T-cell attractant CXCL11
[12,13]. Dysregulation of cellular miRNAs following B cell
infection has also been described [11,14,15,16,17]. The cellular
miRNAs 146a and 155 regulate lymphocyte signaling and gene
expression pathways in this context.
Three general patterns of viral gene expression have been
identified in EBV-associated cancers [1,2]. Latency I is charac-
terized by expression of EBNA-1, while latency II is characterized
by expression of EBNA-1 along with LMP1 and 2. Latency III is
characterized by expression of all EBNAs and LMPs and is
typically associated with B cells infected with EBV in vitro or in
lymphomas in the immunosuppressed. EBV miRNAs are
expressed in all EBV infected tumor cells, although they are
differentially expressed in some tumors [3,4,5,6,7,18,19,20,21].
The context in which miRNA functions are investigated may be
particularly important since the ubiquitous and powerful activities
of all the latent proteins expressed in latency III could mask some
of the activities contributed by miRNAs. Recently, several cell
lines have been isolated from EBV-associated NKT cell lympho-
mas, which appear to select for latency II in both primary tumor
tissues as well as the cell lines [22,23]. Thus, NKTCL cell lines
may be a powerful model system to investigate the functions of
EBV gene products within the context of latency II and may lead
to insights into miRNA functions in EBV-associated HD, GC, and
NPC, for which few practical cell culture systems are available.
Nasal NK/T cell lymphomas (NKTCL) are a heterogeneous
group of tumors, so named because some tumors have an NK
phenotype (CD3
2, CD56
+) and some have a T cell phenotype
(usually CD4
+/CD3
+, but sometimes CD8
+ CD3
+ and sometimes
CD3
+ 4
2,8
2 gamma delta) [24,25]. NKTCL is a distinct clinical
entity characterized by necrotic lesions in the nasal cavity,
nasopharynx, and palate. These are generally aggressive tumors
with poor prognosis [24,25]. A universal feature of these tumors is
the consistent and strong association with EBV, although the
precise role of the virus in this disease remains poorly understood.
Analysis of primary tumor tissue has shown a latency II pattern of
EBV gene expression [22,23]. At least 7 cell lines of both NK and
T cell-like phenotypes have been derived from primary tumors.
These include NK-like (CD3
2, CD56
+) SNK1, -6, -10 and T-cell-
like (CD3
+, CD56
+, TCRc/d
+) SNT 8, -13, 15, -16 cell lines
[22,23]. The cell lines, like the primary tumor tissues from which
they were derived, retain latency II EBV expression patterns and
the EBV genome is clonal. EBV expresses more than 40 miRNAs,
but which ones are expressed in NKTCL remains unknown. We
hypothesized that specific viral and cellular miRNAs are likely to
play a role in the genesis and maintenance of NKTCL. To address
this, we utilized microarrays and quantitative PCR to identify
EBV miRNAs that are expressed in established NKTCL cell lines.
Transfection of antisense oligonucleotides to some of the
abundantly expressed EBV miRNAs revealed that at least one of
them, BART9, contributes significantly to NKTCL proliferation.
The results provide new information about the expression pattern
of EBV encoded miRNAs in NKTCLs and identified a novel
function for the EBV-encoded BART9 miRNA.
Results
NKTCL stably maintain the EBV Type II latency program
In tumors, EBV displays latency programs characterized by
specific patterns of viral gene expression. In Burkitt’s lymphoma,
Type I latency is seen while Type II latency is observed in
nasopharyngeal carcinoma, gastric carcinoma, and Hodgkin’s
disease. Type III latency is often restricted to B lymphomas in
immunodeficient patients [26]. Although previous studies have
found that NKTCLs have a type II latency phenotype, it is
common for some EBV positive cell lines to drift towards type III
latency in culture. To confirm the latency phenotype under our
culture conditions, we tested five NKTCL cell lines for latent and
lytic gene expression. We found that the two SNK (SNK6 and
SNK10) and three SNT (SNT8, SNT15 and SNT16) cell lines
expressed EBNA1 and LMP1 (Figure 1A). These cell lines did not
express the other EBNA proteins, EBNA-LP, EBNA3C and
EBNA2 (Figure 1B). We also found that there was no expression of
Figure 1. Characterization of NK T cell lymphoma cell lines by immunoblot analysis. Cell lysates were prepared from two NK-like (SNK6,
SNK10) and three T cell-like (SNT8, SNT15 and SNT16) NKTCLs. Immunoblots were performed to analyze the expression of the indicated EBV latent
and lytic proteins. EBV negative DG75 cells were used as a negative control and EBV positive MHK cells, which maintain Latency III gene expression
and express all of the latent proteins, were used as a positive control.
doi:10.1371/journal.pone.0027271.g001
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cell lines stably exhibit a Type II latency program.
miRNA microarray profiling of NKTCL
Nasal NK/T cell lymphomas (NKTCLs) have been demon-
strated to be consistently associated with Epstein-Barr virus (EBV)
as all cases are EBV positive [27,28,29]. EBV encodes at least 40
microRNAs (miRNA) [3] and there is increasing evidence for the
role that miRNAs play in malignant transformation of cells [30].
Therefore, to investigate the role of EBV miRNAs in NKTCL
oncogenesis, we first carried out miRNA microarray profiling. We
isolated total RNA from two representative NKTCL cell lines,
SNK6 and SNT16. Both SNK6 and SNT16 express cellular and
EBV proteins that are consistent with prototypical NK and T-cell
like NKTCLs respectively. These cell lines were also chosen for
microarray profiling and further analysis because of their robust
growth and viability in cell culture relative to other known SNK or
SNT cell lines. A miRHumanVirus microarray chip was used to
examine the expression levels of 1100 mature miRNAs that
included human (875) and viral (225) miRNAs. The probes also
included 44 EBV miRNAs in the microarray chip.
We used the criteria and statistical parameters described in the
Methods to analyze the EBV miRNA expression patterns in the
two NKTCL cell lines. Using a median expression value cut-off of
500, we identified 19–21 EBV miRNAs that were present at
relatively high levels in SNK6 and SNT16 cell lines (Fig. 2A). To
verify the reliability of the microarray data, we selected seven EBV
miRNAs whose expression in the microarray ranged from high to
low and carried out Taqman PCR on total RNA extracted from
SNK6 and SNT16 cells. To more easily compare the relative
expression levels of these miRNAs to previous studies, miRNA
levels are shown normalized to either 10 pg total RNA or as copy
numbers per cell. As shown in Figure 2B and C, the relative
expression level of EBV miRNAs BART17-5p, BART7, BART1-
3p, BART9, and BART10 was at least one log higher than EBV
miRNA BART2-3p in both SNK6 and SNT16 cells. The levels of
the miRNAs were also higher in SNT16 cells than SNK6 cells.
This is in agreement with the microarray data which also showed a
higher expression level of the selected miRNAs in SNT16 cells
compared to SNK6 cells (Fig. 2B). Notably, BHRF1 derived
miRNAs were nearly undetectable (Fig. 2A–C). These data
indicate that the microarray profiling data are generally reliable
and this analysis has therefore determined the set of EBV miRNAs
which are expressed in the SNK6 and SNT16 cell lines.
Reducing EBV miRNA levels affect SNK6 and SNT16
growth rate
miRNAs regulate many genes including, those involved in cell
growth [31]. We first investigated the consequences of blocking
EBV miRNA function on the growth rate of SNK6 and SNT16
NKT-cell lines. Based on the miRNA microarray profile (Fig. 2),
we chose six EBV miRNAs that were expressed at high levels in
both cell lines. The six EBV miRNAs were individually inhibited
by transfection LNA-modified antisense oligonucleotides. Samples
were collected every 24 hours for three days and cell numbers and
viability analyzed. The anti-EBV-miR-BART9, anti-EBV-miR-
BART7 and anti-miR- BART17-5p showed a statistically
significant reduction in SNK6 cell growth (,19%, ,20% and
,29%, respectively) (Fig. 3A). EBV-miR-BART1-5p and EBV-
miR-BART16 antisense oligonucleotides did not have statistically
significant effects on SNK6 growth rate. Also there was no
significant effect on the viability of the SNK6 cells upon inhibition
of any of the EBV miRNAs shown in Figure 3A (Fig. 3B). In
SNT16 cells, only anti-EBV-miR-BART9 showed a statistically
significant decrease (,34%) in cell growth. Anti-EBV-miR-
BART16, anti-EBV-miR-BART17-5p, anti-EBV-miR-BART7,
anti-EBV-miR1-5p affected cell growth by ,25%, ,3%, ,10%
and ,7%, respectively, but these differences were not statistically
significant in a paired t-test (Fig. 3C). We noted that there was a
decrease of ,20% in viability of SNT16 cells when the levels of
EBV miRNAs were reduced (data not shown). Anti-EBV-miR-
BART1-3p showed an increase in SNK6 and SNT16 cell growth,
but this difference was not statistically significant (Fig. 3A and C).
A scrambled control miRNA had no detectable effect on
proliferation or viability on either cell line (Fig. 3). This data
suggests that the expression levels of some EBV miRNAs may play
a role in cell proliferation.
Inhibiting EBV miR-BART9 reduces LMP1 protein and
mRNA expression in SNK6 cells
Because reducing BART9 levels affected growth rate in SNK6
and SNT16 cells (Fig. 3), we focused further experiments on the
BART9 miRNA. EBV-encoded LMP1 triggers multiple cellular
signaling pathways that influence cell growth [32]. We carried out
immunoblot analysis to investigate if the effect on growth rate
upon reduction of EBV BART miRNA was a result of altered
LMP1 expression. SNK6 cells were transfected with either control
miRNA (Scramble) or anti-EBV-miR BART9 and cells were lysed
96 hours post-transfection. Immunoblots were performed and
probed for LMP1 levels. We found that inhibiting EBV miR-
BART9 reduced LMP1 protein expression by almost 50% when
normalized to the Hsp70 loading control and relative to the
control miRNA (Fig. 4A). In these experiments, we also probed for
lytic protein Zta in order to examine if the activation of EBV lytic
program was the reason for reduced SNK6 cell growth rate and
found no detectable expression of Zta protein (data not shown).
We also investigated the kinetics of anti-EBV-miR-BART9 effect
on LMP1 level by carrying out a time-course experiment. We
observed that there was a ,46% reduction of LMP1 protein level
96 hours post-transfection of anti-EBV-miR-BART9 compared to
control miRNA (Fig. 4B).
We next examined if the ,50% reduction in LMP1 protein
level following inhibition of BART9 was a consequence of reduced
LMP1 mRNA expression. SNK6 cells were transfected with anti-
EBV-miR-BART9 and total RNA extracted from the cells
96 hours post-transfection. cDNA was synthesized and Q-PCR
was performed using LMP1 specific primers. We found that there
was ,2-fold decrease in the LMP1 mRNA levels when BART9
was inhibited (Fig. 4C). This data suggests that BART9 miRNA
functions as a positive factor for LMP1 at the level of mRNA
accumulation.
EBV miR-BART9 has a positive effect on LMP1 protein and
mRNA expression in SNK6 cells
If BART9 does indeed have a positive influence on LMP1
expression, then increasing its level might be predicted to increase
LMP1 expression, in contrast to the effect of the antisense BART9
miRNA (Fig. 3, 4). To test this prediction, we transfected a
precursor for miRNA-BART9 (pre-EBV-miR-BART9) into
SNK6 cells and performed immunoblots and Q-RT-PCR to
examine levels of LMP1 protein and mRNA, respectively. We
found that increasing BART9 levels increased LMP1 protein
expression by ,33% relative to cells transfected with the precursor
negative control miRNA (pre-NegCtrl) when normalized to the
loading control b-actin (Fig. 5A). We also found that over
expressing BART9 increased the LMP1 mRNA level by a factor of
1.7 (Fig. 5B).
EBV miRNAs in NKT Cell Lymphomas
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SNK6 cell growth
The role of LMP1as the oncoprotein of EBV is dependent on its
expression level. While LMP1 has been reported to promote
cellular transformation, increased expression of LMP1 can inhibit
cell growth [33]. We next investigated whether increasing BART9
levels would inhibit SNK6 cell growth. Precursor BART9 was
transfected into SNK6 cells and samples were collected every
24 hours for three days and cell numbers and viability analyzed.
We found that increasing BART 9 levels modestly (,8%) affected
SNK6 cell growth rate (Figure 6A) without affecting viability
(Figure 6B). Although the data for reduction in growth rate of
SNK6 following over-expression of BART9 did not show a
statistically significant difference in a paired t-test, the results of
three independent experiments showed a clear and reproducible
trend of reduced growth. This suggests that the level of LMP1
needs to be regulated stringently as an increase (Figure 6) or
decrease below a threshold point (Figure 3 and 4) has an inhibitory
effect on SNK6 cell growth. To determine whether the effects of
BART9 miRNA on LMP1 expression are directed through the
39UTR of the LMP1 mRNA, we cotransfected a BART 9 miRNA
precursor with an LMP1 expression plasmid containing the
natural 39UTR and a plasmid lacking this element in HeLa cells.
Under these conditions, BART9 had no effect on LMP1
expression from either expression plasmid, suggesting that the
effects of BART9 on LMP1 expression are indirect (data not
shown).
Discussion
In this study we show that ,20 EBV miRNAs are abundantly
expressed in Nasal NK/T cell lymphomas (NKTCL). We also
provide evidence that modulating EBV miRNA levels impacts
NKTCL growth rate. Furthermore, we found a direct correlation
between levels of EBV-miR-BART9 and LMP1 protein and
mRNA expression. Together, these observations suggest that
BART9 miRNA positively modulates expression of LMP1 and
one manifestation of perturbing this regulation is a retardation of
NKTCL cell growth.
A number of studies have characterized EBV miRNA
expression and their roles in nasopharyngeal carcinomas
[4,11,19]. Other studies have focused on the role of cellular
miRNAs in NKTCLs [34] and other human cancers [35]. While
EBV miRNAs have been found to be conserved evolutionarily [3],
they are differentially expressed in different cell types [3,7].
However, to our knowledge this is the first study to determine the
expression of EBV miRNAs in NKTCLs. We found that at least
19 EBV miRNAs are abundantly expressed in NKTCLs. Indeed,
these 19 miRNAs appear to be expressed at levels 2–3 logs higher
than their expression in NPCs [19]. We note that a limitation of
our study is that only two NKTCL cell lines and no primary
tumors were profiled. Nevertheless, our data suggest that even
though EBV viral gene expression might be similar to NPC and
Hodgkin disease [36], miRNA expression could vary greatly
between these two tumors.
What role might these EBV miRNAs play in NKTCLs? Cancer
is a disease where cell proliferation is dysregulated. A number of
studies have demonstrated a connection between miRNAs and
cellular differentiation and in many instances miRNAs act as
oncogenes by down-regulating tumor suppressors [30,37]. In this
study, we found that inhibiting EBV miRNAs slowed the growth
rate of NKTCLs. This reduction in proliferation was not because
of loss of cell viability. These EBV miRNAs may be functionally
analogous to cellular miRNAs like miR- 106b that targets the cell
cycle inhibitor p21
Cip1 [38] or miR-221 and miR-222 that regulate
p27
kip1 [39]. Since EBV miRNAs are evolutionarily conserved [3],
it is also possible that they target viral proteins as is the case with
EBV-miR-BART17-5p that has been reported to regulate LMP1
[11] or EBV-miR-BART2 that down-regulates BALF5 viral DNA
polymerase [10]. In the SNK6 cell line we observed that inhibiting
EBV-miR-BART9 reduced the level of LMP1 mRNA and
protein. Furthermore, over-expression of BART9 miRNA resulted
in increase of LMP1 protein and transcript levels. This suggests
that in NKTCLs, BART9 miRNA likely regulates LMP1 mRNA
expression and we favor the hypothesis that this is an indirect
regulation as a reporter plasmid containing the 39 UTR of the
LMP1 mRNA was not responsive to BART9 in transient
expression experiments (data not shown). BART9 may indirectly
up-regulate LMP1 by targeting a repressor of its expression. When
BART9 is inhibited, the level of this putative repressor may be
increased resulting in decrease of LMP1 transcript and protein
levels. Alternatively, BART9 may be involved somehow in
maintaining LMP1 mRNA stability which has been reported to
have a long half-life [40]. In this scenario, BART9 may stabilize
LMP1 mRNA, and inhibition of BART9 thus renders the LMP1
mRNA susceptible to degradation.
A tight regulation on the expression of LMP1 is beneficial to
EBV and its survival in infected cells. For instance, if LMP1
expression is consistently high, it can either result in cell growth
arrest [41], inhibit viral and cellular promoters [42] or enhance
epitope presentation to cytotoxic T cells [43]. However, under
certain conditions, it might be beneficial for EBV to induce LMP1
expression for a short period of time. Notably, a recent study
reported the transient upregulation of LMP1 by the p38 signaling
pathway [44].
In summary, we have shown that 19 EBV miRNAs are
abundantly expressed in NKTCLs and their levels are likely to be
important in maintaining cell growth. Our data also indicate that
EBV BART9 is involved in regulating LMP-1 expression in these
cells. This has implications in mechanisms of lymphomagenesis
and future experiments could be directed at investigating the role
of EBV miRNAs and its regulation of cellular targets.
Methods
Cell lines
The NK-T cell lymphoma (NKTCL) cell lines, SNK6, SNK10,
SNT8, SNT15, SNT16 were obtained from Norio Shimizu
(Tokyo Medical and Dental University). The cells were cultured in
RPMI1640 supplemented with 10% fetal bovine serum, 1%
Figure 2. MiRNA expression profile in NK T cell lymphoma cell lines. (A) The table shows the median expression values from normalized,
log-ratio (base 2) data sets of representative EBV miRNAs in SNK6 and SNT16 cell lines arranged in a descending order of expression levels. (B)
Taqman qPCR for selected EBV miRNAs in SNK6 and SNT16 cells. The indicated EBV miRNAs were quantified using a stem-loop PCR protocol
described by Chen et al [46] for detecting miRNAs. The copy number of each of the miRNAs was determined by reverse transcription and
amplification of synthetic miRNAs. The graph represents miRNA expression as molecules per 10 picogram RNA. (C) Taqman qPCR for indicated EBV
miRNAs in SNK6 and SNT16 cells as described in (B). The data are presented as copy number of EBV miRNA per cell.
doi:10.1371/journal.pone.0027271.g002
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B; Invitrogen) and 600 IU of IL-2.
MiRNA microarray analysis and validation
Total RNA was isolated from SNK6 and SNT16 cells using the
miRNAeasy kit (Qiagen) as per manufacturer’s protocol. RNA was
analyzed by LC Sciences (Houston, TX) with miRNA microarrays
using the mParaflo microfluidic chip technology and all data is
MIAME compliant. The detailed process can be found at http://
www.lcsciences.com. Briefly, photogenerated reagent chemistry
probes for miRNAs were in situ synthesized on chips with three
repeats for each probe to allow for statistical analysis. MiRHu-
manViruses version 13 arrays were used to detect a total of 1100
unique mature miRNAs comprising of 875 human miRNAs and
225 virus miRNAs. The virus miRNAs included 44 EBV miRNAs.
RNA samples from SNK6 and SNT16 cells were labeled with Cy3
for hybridization. The chips included 50 control probes based on
Sanger miRBase Release 13 with four-sixteen repeats. The control
probes were used for quality controls of chip production, sample
labeling and assay conditions. Included in the control probes were
PUC2PM-20B and PUC2MM-20B which are the perfect match
and single-base match detection probes, respectively, of a 20-mer
RNA positive control sequence that is spiked into the RNA
samples before labeling. For a transcript to be listed as detectable
three conditions had to be met: (1) signal intensity had to be
greater than three times background standard deviation; (2) spot
co-variance (CV), defined as ratio of standard deviation over signal
intensity had to be less than 0.5; (3) the signals from at least 50% of
the repeating probes had to be above detection level. Data was
normalized using a cyclic LOWESS (Locally-weighted Regression)
method [45] to remove system related variations such as sample
amount variations, dye labeling bias, and signal gain differences
between scanners to reveal biological relevant variations. A t-test
was performed on the signals obtained for the repeating probes
and p-value calculated. MiRNAs were defined as differentially
expressed if they had a p-value,0.01. Clustering analysis was
performed with a hierarchical method using average linkage and
Euclidean distance metric. The clustering data was represented as
a heat map using TIGR MeV (Multiple Experimental Viewer;
The Institute for Genomic Research). The microarray data has
been deposited in GEO database with accession number
GSE30695.
Validation of miRNA microarray
Selected EBV miRNAs were quantified using a PCR protocol
described by Chen et al [46] for detecting miRNAs. Briefly, stem-
loop primers complementary to specific EBV miRNAs were
designed as described by Cosmopoulos et al [19]. For each miRNA
assayed, 100 ng of total RNA was reverse transcribed using a
TaqMan MicroRNA RT kit as described by the manufacturer and
a specific stem-loop primer at a final concentration of 50 nM.
RNA was prepared using an RNeasy kit (Qiagen) from
exponentially growing tissues culture cells. Each 20 ul PCR
reaction contained 1 ul of RT product, 16TaqMan Universal
master mix, 1.5 uM forward primer, 0.7 uM reverse primer, and
0.2 uM probe. The reactions were incubated in a 48-well plate at
95uC for 3 min, followed by 40 cycles of 95uC for 15 s and 60uC
for 30 s. The copy number of each of the miRNAs was determined
by reverse transcription and amplification of synthetic miRNAs
that were identical to the published sequences.
miRNAs and transfection
The miRCURY locked nucleic acid (LNA) modified antisense
oligonucleotides to EBV BART miRNAs (anti-EBV-miR-BART)
were purchased from Exiqon. The sequence of the antisense
oligonucleotides are as follows: Scramble Negative Control (59-
GTGTAACACGTCTATACGCCCA -39); anti-EBV-miR-BART9
(59- ACTACGGGACCCATGAAGTGTTA- 39); anti-EBV-miR-
BART17-5p (59- CTTGTATGCCTGCGTCCTCTTA-39); anti-
EBV-miR-BART7 (59- CCCTGGACACTGGACTATGATG-39);
anti-EBV-miR-BART1-3p (59- GACATAGTGGATAGCGGTG-
CTA-39); anti-EBV-miR-BART1-5p (59- CACAGCACGTCAC-
TTCCACTAAGA-39); anti-EBV-miR-BART16 (59FAM- AGAG-
CACACACCCACTCTATCTAA-39). Precursor EBV miRNA
(pre-EBV-miR) was designed based on the sequence in miRBase
sequence database (http://microrna.sanger.ac.uk/sequences). pre-
EBV-miR-BART9 (59- UAACACUUCAUGGGUCCCGUAGU-
39) and precursor Negative control miRNA (pre-NegCtrl) were
ordered from Ambion/Applied Biosystems.
SNK6 and SNT 16 cells were seeded at 1610
6 cells in 24- well
tissue culture plates and transfected with antisense or precursor
miRNAs using Oligofectamine or Lipofectamine RNAimax
according to the manufacturer’s protocol. Transfection efficiency
of the miRNAs in SNK6 and SNT 16 cells was determined with
FAM labeled EBV- BART16 miRNA and was found to be nearly
98% as determined by flow cytometry (data not shown). Cell
viability following transfections was measured by Trypan Blue
exclusion and found to be ,95%.
RT-real time PCR for EBV mRNAs
Independent transfections of anti-EBV-miR-BART 9 or pre-
EBV-miR-BART 9 were performed in SNK6 cells. The controls
transfected were either Scramble-miRNA (Exiqon) or Precursor-
Negative Control (Pre-NegCtrl) (Applied Biosystems), respectively,
as described above. Total RNA was isolated using RNeasy mini kit
(Qiagen) and RT-real-time-PCR assays carried out for quantifi-
cation of LMP1 and a-tubulin levels using the Bio-Rad MyIQ
single color detection system. Briefly, 10 ng of cellular RNA was
reverse transcribed into cDNA using the iScript cDNA synthesis
kit (Bio-Rad) in a 20 ml reaction using the manufacturer’s protocol.
Quantitative real-time PCR was performed using 3 ml of the
synthesized cDNA and the iQ
TM SYBR Green Supermix (Bio-
Rad). PCR reactions were carried out in 96-well format using a
Bio-Rad iCycler. Analysis was done by the MyIQ software
program (Bio-Rad) and the fold-changes were calculated using the
DDCt method as previously described [47] with a-Tubulin as the
housekeeping gene control. The primer sequences used for LMP1
have been described previously [48] and were LMP1 (forward) - 59
Figure 3. Inhibiting EBV BART miRNA levels affect NKTCL growth rate without affecting cell viability. (A) SNK6 cells were transfected
with antisense to the indicated EBV miRNAs and cell numbers counted every 24 hours for three days. Cell growth rate was calculated as difference in
cell numbers between the 24 hour and 72 hour time point and compared with cells transfected with control Scramble miRNA. Data shown are the
average 6 SD from three independent experiments. (* represents p value of #0.05 in a paired t-test). (B) SNK6 transfected with antisense EBV
miRNAs were analyzed for viability by Trypan blue exclusion in a Vi-CELL counter every 24 hours for three days. The data presented is the cell viability
at 72 hours post-transfection and is the average 6 SD from three independent experiments. (C) SNT16 cells were transfected with antisense to the
indicated EBV miRNAs and cell growth rate analyzed as described above. Data shown are the average 6 SD from three independent experiments.
(* represents p value of ,0.05 in a paired t-test).
doi:10.1371/journal.pone.0027271.g003
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59ACCAAGTCGCCAGAGAATCTCCAA 39. The primers for
a-Tubulin were, a-Tubulin (forward) - 59 CCTGACCACCCA-
CACCACAC 39, a-Tubulin (reverse) - 59 TCTGACTGAT-
GAGGCGGTTGAG 39.
Cell proliferation functional assay
SNK6 and SNT16 cells were seeded in 96 well plates at 8610
5
cells in 100 ml/well and transfected with 100 pmol of indicated
anti-EBV-miRNAs or pre-EBV-miRNAs or control Scramble-
miRNA or Pre-Neg-Ctrl. In some experiments, the cells were
Figure 4. Immunoblot and Q-RT-PCR analysis of LMP1 expression in SNK6 following inhibition of EBV-BART9 miRNA. (A) SNK6 cells
were transfected with anti-EBV-BART9 miRNA or Scramble control miRNA and cell lysates prepared 96 hours post-transfection. LMP1 protein
expression was analyzed in immunoblots. When compared to cells transfected with control miRNA and normalized to b-actin loading control,
quantification of immunoblots showed that BART9 inhibition reduced LMP1 protein levels by ,50%. (B) SNK6 cells were transfected with control or
anti-EBV-BART9 miRNA and samples collected every 24 hours in a time-course experiment. Cell lysates were prepared and immunoblot analysis
carried out to determine LMP1 expression. Quantification of LMP1 levels using Image J as described above showed that LMP1 protein levels are
reduced only at later time-point. (C) SNK6 cells were transfected with either anti-EBV-BART9 or control miRNA and cells collected 96 hours post-
transfection. Total RNA was extracted and cDNA synthesized using iScript cDNA synthesis kit. Using LMP1 specific primers, Q-PCR was carried out and
data analyzed using the DDCt method. Data shown is the average 6 SD from three independent experiments. (** represents p value of ,0.005 in a
paired t-test).
doi:10.1371/journal.pone.0027271.g004
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6 cells/well. After overnight incubation, the cells
were transferred into 24 well tissue culture plates. Cells were
collected every 24 hours and analyzed for cell number and
viability using the Becton-Dickinson Vi-CELL counter at the
Baylor College of Medicine Flow Cytometry Core. The cell
counter uses trypan blue exclusion to automatically stain and
count cells, as well as assay cell size and viability.
Immunoblotting
Cells following treatment were lysed with EBCD buffer (50 mM
Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% NP-40, 5 mM dithio-
threitol) containing protease inhibitor cocktail (Sigma). Immuno-
blotting was performed as described previously [49]. Monoclonal
antibodies used in this study include, LMP1 (S12), EBNA-LP
(JF186), EBNA3C (A10), and EBNA2 (R3). Other antibodies
Figure 5. Precursor EBV-BART9 miRNA increases LMP1 protein and mRNA levels in SNK6 cells. (A) SNK6 cells were transfected with
precursor EBV-BART9 or control miRNA. The cells were collected 96 hours post-transfection and cell lysates prepared for immunoblot analysis.
Quantification of immunoblots showed a ,33% increase in LMP1 protein levels in cells transfected with EBV miRNA compared to control miRNA
transfected cells when normalized to loading control. Data shown is a representative immunoblot from three independent experiments. (B) Total
RNA was extracted from SNK6 cells transfected with precursor EBV-BART9 or control miRNA. Following cDNA synthesis, LMP1 mRNA levels were
analyzed by Q-RT-PCR. Data presented is the average 6 SD from three independent experiments. (* represents p value of ,0.05 in a paired t-test).
doi:10.1371/journal.pone.0027271.g005
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PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27271obtained commercially included EBNA1 (1EB12, Santa Cruz), Zta
(Argene), b-Actin (Sigma) and a-tubulin (Sigma). HRP secondary
antibodies were obtained from Jackson Immunolaboratories and
Western blots were developed using the SuperSignal West pico kit
(Thermo Scientific). Immunoblots were quantified using Image J
software [50].
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